ZURICH (Reuters) - Novartis said on Monday its drug Votubia had received approval from the European Commission for treating non-cancerous kidney tumors in patients with a rare genetic disease known as tuberous sclerosis complex (TSC).

This marks the first approval of a medical treatment in this patient population in Europe, Novartis said.

(Reporting by Catherine Bosley)